Effects of subclinical hypothyroidism treatment on psychiatric symptoms, muscular complaints, and quality of life

• Autor(a) principal: Reuters,Vaneska Spinelli
• Data de Publicação: 2012
• Outros Autores: Almeida,Cloyra de Paiva, Teixeira,Patrícia de Fátima dos Santos, Vigário,Patrícia dos Santos, Ferreira,Márcia Martins, Castro,Carmen Lucia Natividade de, Brasil,Marco Antônio, Costa,Antônio José Leal da, Buescu,Alexandru, Vaisman,Mário
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Arquivos Brasileiros de Endocrinologia & Metabologia (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302012000200006
• topic: Anxiety; depression; quality of life; levothyroxine

OBJECTIVES: To evaluate the impact of subclinical hypothyroidism (sHT) treatment on health-related quality of life (QoL), psychiatric symptoms, clinical score, and muscle function. MATERIALS AND METHODS: In this randomized double-blind study, patients were assigned either to treatment (n = 35) or placebo (n = 36). Clinical and psychiatric symptoms were assessed by the Zulewski, Hamilton and Beck scales. QoL was assessed by the SF-36 questionnaire. Assessments of quadriceps (QS) and inspiratory muscle (IS) strength were performed by a chair dynamometer and a manuvacuometer. RESULTS: Treatment improved IS (+11.5 ± 17.2; p = 0.041), as did QoL domains "Pain" and "Role Physical" (+19.7 ± 15.2, 0.039 and +22.1 ± 47.5, p = 0.054; respectively). Clinical and psychiatric symptoms showed similar responses to both interventions. CONCLUSIONS: sHT treatment improved IS and physical aspects of QoL, despite no impact in other muscle parameters. Clinical score, psychiatric symptoms, and SF-36 domains, based on mental dimensions of QoL may be more susceptible to "placebo effect" in patients with sHT.